10 In the DAPA-HF trial, among 4,700 patients with a significantly reduced mean LVEF (31% 6.7), most classified as New York Heart Association (NYHA) class II, dapagliflozin provided a 26% RR reduction in the primary composite outcome (CV death, HF hospitalisation and urgent visits for worsening HF), regardless of the presence or absence of type 2 diabetes (T2D), with a NNT of 21
The money that I invested in this training has been recovered in less than 1 month
What may be the clinical differentiators
Average cumulative weight loss reaches 8 to 12 pounds
More than 98% of total glutathione is present as GSH and the rest is found as the oxidised form, glutathione disulfide (GSSG) or a range of glutathione-S-conjugates
Brain insulin resistance in alzheimers disease and related disorders: mechanisms and therapeutic approaches